IVC Stock Overview
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.36|
|52 Week High||US$8.83|
|52 Week Low||US$0.80|
|1 Month Change||44.68%|
|3 Month Change||-3.55%|
|1 Year Change||-83.15%|
|3 Year Change||-73.75%|
|5 Year Change||-89.62%|
|Change since IPO||-48.80%|
Recent News & Updates
|IVC||US Medical Equipment||US Market|
Return vs Industry: IVC underperformed the US Medical Equipment industry which returned -25.7% over the past year.
Return vs Market: IVC underperformed the US Market which returned -20.4% over the past year.
|IVC Average Weekly Movement||14.0%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: IVC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IVC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and Küschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand. It also provides lifestyle products, including pressure relieving overlays and mattress systems under the Invacare Softform and microAIR brands; safe patient handling products under the Birdie, Evo, and ISA brands; residential and institutional care beds and bed accessories, and manual wheelchairs under the Invacare brand name; and personal care products.
Invacare Fundamentals Summary
|IVC fundamental statistics|
Is IVC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IVC income statement (TTM)|
|Cost of Revenue||US$645.05m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.56|
|Net Profit Margin||-6.35%|
How did IVC perform over the long term?See historical performance and comparison
Is IVC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IVC?
Other financial metrics that can be useful for relative valuation.
|What is IVC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IVC's PS Ratio compare to its peers?
|IVC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
RWLK ReWalk Robotics
TRIB Trinity Biotech
Price-To-Sales vs Peers: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does IVC's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is IVC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.06x|
|Fair PS Ratio||0.6x|
Price-To-Sales vs Fair Ratio: IVC is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Share Price vs Fair Value
What is the Fair Price of IVC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IVC ($1.36) is trading below our estimate of fair value ($9.56)
Significantly Below Fair Value: IVC is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IVC's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Invacare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVC's revenue (2.5% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: IVC's revenue (2.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IVC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Invacare performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVC is currently unprofitable.
Growing Profit Margin: IVC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVC is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.
Accelerating Growth: Unable to compare IVC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: IVC has a negative Return on Equity (-29.43%), as it is currently unprofitable.
Discover strong past performing companies
How is Invacare's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IVC's short term assets ($350.5M) exceed its short term liabilities ($233.2M).
Long Term Liabilities: IVC's short term assets ($350.5M) do not cover its long term liabilities ($444.8M).
Debt to Equity History and Analysis
Debt Level: IVC's net debt to equity ratio (137.1%) is considered high.
Reducing Debt: IVC's debt to equity ratio has increased from 36.9% to 164.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IVC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Invacare current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IVC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IVC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: IVC is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IVC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Monaghan (53 yo)
Mr. Matthew E. Monaghan, also known as Matt, has been the Chief Executive Officer and President of Invacare Corporation since April 01, 2015 and has been its Chairman of the Board since May 14, 2015. Mr. M...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD5.99M) is above average for companies of similar size in the US market ($USD759.63K).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
Experienced Management: IVC's management team is considered experienced (3.3 years average tenure).
Experienced Board: IVC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Invacare Corporation's employee growth, exchange listings and data sources
- Name: Invacare Corporation
- Ticker: IVC
- Exchange: NYSE
- Founded: 1885
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$48.482m
- Shares outstanding: 35.65m
- Website: https://www.invacare.com
Number of Employees
- Invacare Corporation
- One Invacare Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.